ENDOCRYNE LIMITEDActive
Key figures
Like most small UK companies, ENDOCRYNE LIMITED does not publish a profit and loss account in its latest accounts. The figures below come from the balance sheet.
Ratios
2024/25Balance sheet structure
Filed accounts2019/20–2024/25
| 2020/21 | 2021/22 | 2022/23 | 2023/24 | 2024/25 | |
|---|---|---|---|---|---|
| Total assets | 82,253 | 66,255 | 58,178 | 70,255 | 66,700 |
| Total liabilities | 100,225 | 137,327 | 169,012 | 186,560 | 172,380 |
| Net assets / total equity | -18,422 | -71,916 | -112,335 | -101,345 | -90,785 |
| Average number of employees | 1 | 1 | 1 | 1 | 0 |
A dash (—) means no accounts were filed for that year or the item is not in the accounts; 0 is a zero stated in the accounts. Small companies usually file only a balance sheet, so the profit and loss account is often missing.
Summary: ENDOCRYNE LIMITED
Company
ENDOCRYNE LIMITED is a private limited company registered with Companies House under company number SC624702. It was incorporated on 18 Mar 2019. Its status is active. The registered office is in Edinburgh (EH12). Its nature of business (SIC 2007) is growing of spices, aromatic, drug and pharmaceutical crops (01280), manufacture of basic pharmaceutical products (21100), manufacture of pharmaceutical preparations (21200), research and experimental development on biotechnology (72110).
Accounts
The latest accounts in the database are for 2024/25 (period ending 31 Mar 2025); the company files micro-entity accounts. Net assets were −£90,785, up 10.4% on the previous year. Total assets were £66,700 and total liabilities £172,380. The company had an average of 0 employees. Figures are available for 6 financial years (2019/20–2024/25).
Control and charges
One person with significant control is registered.
Filing deadlines
The next accounts are due by 31 Dec 2026. The next confirmation statement is due by 31 Mar 2027.